Why EY
R&D has been a key focus area for most Indian pharma companies. Though India is a leader in terms of ANDA approvals globally, there is a significant scope for improving the same to achieve faster launches. We have been working with leading pharma companies to transform their R&D organizations. As a part of the transformation program, we have delivered a reduction in end-to-end timelines (Initiation to Launch) of ~15 to 20%, improving FTR (First Time Right) to >85% across R&D processes. We look at R&D from an enterprise-wide perspective, including critical elements of people, process, and technology. The typical transformation journey kicks off by re-designing the organization structure to support the agreed to-be processes. Once the same is implemented, the processes are enabled with an EY proprietary tool called “R&D Workbench for Pharma.” It is a unique solution, led by experienced professionals with strong global experience of working in R&D technology enablement programs and change management. EY has empowered organizations with several such fit-for-purpose tech platforms and tools, boosting their end-to-end process capabilities.